Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the standard treatment for HR + /HER2− advanced BC (ABC)2,3, with the demonstration of overall survival (OS) benefit in several trials4–7. Here, CDK4 is linked to breast cancer.